The most abundantly studied are MAPK pathway inhibitors, and the common mechanisms of resistance are the reactivation of MAPK pathways such as DUSP7, NF2, and the KEAP1/Nrf2 pathway, which are present in multiple cancer resistance models. The gene discussed is NFE2L2; the disease is cancer.